The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Pooled analysis of long-term data from studies of tandem autologous versus autologous-allogeneic HSCT for newly diagnosed multiple myeloma

Dec 19, 2019

Tandem autologous hematopoietic stem cell transplantation (HSCT) (auto-HSCT) has been studied as a method of increasing remission rates and reducing relapse in the upfront treatment of multiple myeloma (MM). 1,2Autologous HSCT followed by reduced intensity conditioning allogeneic HSCT (auto-allo-HSCT) offers the potential for a long-term graft- versus-myeloma (GVM) effect, but carries a risk of graft- versus-host disease (GvHD) and potentially higher non-relapse mortality (NRM).

Tandem auto-allo-HSCT has been compared with tandem auto-HSCT in multiple prospective studies with conflicting results, leaving clinicians unclear which strategy is preferred for newly diagnosed patients with MM. In 2013, a meta-analysis of published results was performed, which suggested that auto-allo-HSCT was associated with a better chance of a complete response, but with higher NRM and no improvement in PFS or OS compared with tandem auto-HSCT. 3

With the passage of time, many of these studies now have long-term follow-up data available, enabling a fresh analysis of pooled individual patient data from these studies. The latest analysis, which included long-term follow-up data from four of the original meta-analyses, was presented in December 2019 at the 61 stAmerican Society of Hematology Meeting & Exposition, Orlando, US, by Luciano Costafrom the O’Neal Comprehensive Cancer Center at the University of Alabama, Birmingham, US. 4

The Multiple Myeloma Hub is covering transplant in myeloma as a monthly theme. Read more here .

Study design

  • Studies were selected for inclusion that fulfilled the following criteria:
    • Newly diagnosed patients with MM who had received brief induction therapy
    • Allocation to auto-auto-HSCT or auto-allo-HSCT arms based exclusively on the availability of HLA-matched sibling donors (“biologic randomization”)
    • Conditioning regimen for allo-HSCT met Center for International Blood and Marrow Transplant Research ®(CIBMTR)criteria for reduced intensity
  • Investigators from all trials meeting eligibility criteria were invited to submit a limited dataset (age, gender, risk profile, treatment arm, relapse, NRM, PFS, OS)
  • Patients were designated high-risk if they had a β2 microglobulin level at diagnosis of ≥ 4 mg/L and/or a deletion of chromosome 13 by metaphase karyotyping
  • Outcomes analyzed: PFS, OS, NRM, risk of relapse
  • All analyses were by intention-to-treat (ITT) analysis
  • NRM and relapse/progression were analyzed as competing risks
  • Post-relapse survival (PRS) was defined as the time from relapse/progression until death, censored at last follow-up if alive

Patient characteristics

  • Data from four studies were included: BMT CTN 0102, NMAM2000, PETHEMA/GEM2000, and NCT00415987
  • 1,338 patients were included in the analysis ( Table 1)
    • 899 patients underwent auto-auto-HSCT
    • 439 patients underwent auto-allo-HSCT
  • Median follow-up of survivors: 118.5 months
  • Patients receiving auto-allo-HSCT were slightly younger than patients receiving auto-auto-HSCT
  • The median follow-up of survivors was longer in the auto-allo-HSCT group than in the auto-auto-HSCT group

  Table 1.Patient characteristics

Allo, allogeneic; Auto, autologous; HSCT, hematopoietic stem cell transplantation



(n= 899)


(n= 439)

Median follow-up of survivors,months



Median age,years



Age < 50 years

238 (26.4%)

150 (34.2%)


527 (58.6%)

249 (56.7%)


125 (13.9%)

89 (20.3%)


  • PFS and OS were significantly improved after auto-allo-HSCT compared with auto-auto-HSCT ( Table 2)

Table 2.OS, PFS, and NRM in newly diagnosed patients with MM receiving either auto-auto-HSCT or auto-allo-HSCT in four studies

Allo, allogeneic; Auto, autologous; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; NRM, non-relapse survival; PFS, progression-free survival; OS, overall survival



(n= 899)


(n= 439)

HR (95% CI)

p value


Median OS, months (95% CI)

78 (71.5–84.5)

98.3 (81.8–114.7)

HR= 0.84 (0.73–0.97) p= 0.02

5-year OS, % (95% CI)

59.8 (56.6–63)

62.3 (57.8–66.8)

p= 0.37

10-year OS, % (95% CI)

36.4 (32.9–40)

44.1 (39.2–49)

p= 0.01


Median PFS, months (95% CI)

26.4 (23.8–28.9)

24.4 (18.8–30)

HR= 0.85 (0.75–0.95) p= 0.004

5-year PFS, % (95% CI)

23.4 (20.7–26.1)

30.1 (25.8–34.4)

p= 0.01

10-year PFS, % (95% CI)

14.4 (11.8–16.9)

18.7 (15.0–22.4)

p= 0.06


5-year relapse, % (95% CI)

69.7 (66.8–72.6)

52.4 (47.9–56.9)


10-year relapse, % (95% CI)

77.2 (74.5–79.9)

61.6 (56.9–66.3)



5-year NRM, % (95% CI)

6.9 (5.3–8.5)

17.4 (13.9–20.9)


10-year NRM, % (95% CI)

8.3 (6.5–10)

19.7 (16—23.4)


  • For the 214 high-risk patients (125 auto-auto-HSCT, 89 auto-allo-HSCT), 5-year and 10-year PFS rates were significantly higher with auto-allo-HSCT than with auto-auto-HSCT, but there was no difference in OS
  • Median PRS was 41.5 months (95% CI, 36.5–46.4) in the auto-auto-HSCT arm and 62.3 months (95% CI, 47.7–76.9) in the auto-allo-HSCT arm (HR= 0.70; 95% CI, 0.58–0.84; p< 0.001)


The authors of this study have concluded that, compared with auto-auto-HSCT, auto-allo-HSCT is associated with the best long-term outcomes, although the benefits are only evident with long-term follow-up. Auto-allo-HSCT was associated with a lower risk of relapse, longer OS and PFS, and a higher risk of NRM compared with auto-auto-HSCT. Robust improvements in post-relapse survival were attributed to potential cooperation between GVM and novel MM agents. Nevertheless, despite the advantages of auto-allo-HSCT over auto-auto-HSCT demonstrated in this study, the authors suggest that the improved long-term survival benefit should be balanced against the late morbidity such as chronic GvHD.

Expert Opinion

  1. Kröger N. et al., Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002 Aug 1;100(3):755–760. DOI: 10.1182/blood-2002-01-0131
  2. Maloney D.G.  et al.,Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003 Nov 1;102(9):3447–3454. DOI: 10.1182/blood-2002-09-2955
  3. Armeson K.E. et al.,Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant. 2013 Apr;48(4):562–567. DOI: 10.1038/bmt.2012.173
  4. Costa L.J.  et al.,Tandem autologous–autologous vs. autologous–allogeneic transplantation for newly diagnosed multiple myeloma: pooled analysis of 1,338 patients from four trials with long-term follow-up; 2019. Oral Abstract #259: 61st American Society of Hematology (ASH)Meeting & Exposition, Orlando, FL